絞り込み

16639

広告

Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

著者 Mori H , Suzuki H , Omata F , Masaoka T , Asaoka D , Kawakami K , Mizuno S , Kurihara N , Nagahara A , Sakaki N , Ito M , Kawamura Y , Suzuki M , Shimada Y , Sasaki H , Matsuhisa T , Torii A , Nishizawa T , Mine T , Ohkusa T , Kawai T , Tokunaga K , Takah
Therap Adv Gastroenterol.2019 ; 12():1756284819858511.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (57view , 0users)

Full Text Sources

The environment surrounding eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of in the metropolitan area and examined factors concerning successful eradication.
PMID: 31320930 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード